email article
Machine learning (ML) algorithms developed to predict in-hospital mortality after acute MI offered more meaningful gains in model calibration than in accuracy, researchers found.
Parsing through data on 29 variables from the American College of Cardiology (ACC) Chest Pain-MI Registry, extreme gradient descent boosting (XGBoost) and meta-classifier models offered no substantive improvement in discrimination compared with standard logistic regression modeling (C-statistics 0.90 for both vs 0.89), reported Harlan Krumholz, MD, SM, of Yale School of Medicine, and colleagues.
However, the two ML models showed nearly perfect agreement between observed and predicted risk across the risk spectrum. Of the people deemed moderate-to-high risk in logistic regression, 27% were more accurately reclassified as low risk by the XGBoost model and 25% by the meta-classifier model both more consistent with the observed event rates.
This century-old inn on the Outer Banks is getting another chance. Take a look
Feb. 2 John and Pam Buchholz have traveled the world, welcoming new experiences and embarking on adventures.
But Pam Buchholz, who grew up on the coast of Scotland, says she fell in love with Hatteras Island the first time she visited that stretch of North Carolina s Outer Banks.
So when she stumbled across an online listing for the century-old Atlantic Inn last year, she knew she wanted to buy the suffering hotel and breathe new life into it.
There was a problem, though: Coronavirus-related restrictions prevented her husband from visiting the building. So he agreed to buy it without ever seeing it in person.
This century-old inn on the Outer Banks is getting another chance
Feb. 2 John and Pam Buchholz have traveled the world, welcoming new experiences and embarking on adventures.
But Pam Buchholz, who grew up on the coast of Scotland, says she fell in love with Hatteras Island the first time she visited that stretch of North Carolina s Outer Banks.
So when she stumbled across an online listing for the century-old Atlantic Inn last year, she knew she wanted to buy the suffering hotel and breathe new life into it.
There was a problem, though: Coronavirus-related restrictions prevented her husband from visiting the building. So he agreed to buy it without ever seeing it in person.
First-of-its-kind cardiovascular drug gets FDA approval based on study from Canadian VIGOUR Centre
The U.S. Food and Drug Administration has approved the drug vericiguat for use in patients with heart failure. The drug a first-of-its-kind, once-daily oral treatment for patients with worsening chronic heart failure was approved in part thanks to the VICTORIA (Vericiguat Global Study In Subjects With Heart Failure With Reduced Ejection Fraction) clinical study run by researchers at the University of Alberta s Canadian VIGOUR Centre.
As reported in March 2020, vericiguat works by stimulating an enzyme in the body called soluble guanylate cyclase (sGC), which is important for enhancing heart function and helping blood vessels relax to provide better blood flow. In patients with heart failure, sGC is reduced and unable to adequately stimulate cyclic guanosine monophosphate (cGMP), necessary for transmitting chemical signals to blood vessels, which results in vascular and coronary dysfun
E-Mail
The U.S. Food and Drug Administration has approved the drug vericiguat for use in patients with heart failure. The drug a first-of-its-kind, once-daily oral treatment for patients with worsening chronic heart failure was approved in part thanks to the VICTORIA (Vericiguat Global Study In Subjects With Heart Failure With Reduced Ejection Fraction) clinical study run by researchers at the University of Alberta s Canadian VIGOUR Centre.
As reported in March 2020, vericiguat works by stimulating an enzyme in the body called soluble guanylate cyclase (sGC), which is important for enhancing heart function and helping blood vessels relax to provide better blood flow. In patients with heart failure, sGC is reduced and unable to adequately stimulate cyclic guanosine monophosphate (cGMP), necessary for transmitting chemical signals to blood vessels, which results in vascular and coronary dysfunction.